24 May 2012, Brussels, Charlemagne Building, Salon Rouge
At the eve of the Rio+20 Conference, the Directorate-General for Research and Innovation is taking stock on the EU efforts on a sustainable use of water and organises the side session: Water resources for sustainable development - an overview of the international dimension of EU research results from Johannesburg to Rio+20.
Over the past ten years, EU research has enabled considerable advances in the water sector in terms of technology development, impact assessments and its governance. The knowledge created so far is an important basis for the future sustainable development agenda. As the Rio+20 conference approaches, this session will present the main outcomes of water-related research funded by EU programmes, highlighting the role of international collaboration and innovative partnerships. The event will offer an opportunity to discuss achievements to date and remaining gaps in water research in the future sustainability agenda.
15 May 2012, Brussels
The European Commission's in-house science service, the Joint Research Centre, is holding a conference on "Scientific support for growth, jobs and sustainability: the example of the eco-industries". High level speakers from science and industry will discuss the main sectors concerned: water, air quality, waste, energy efficiency and renewable energy sources. The EU Commissioner for research, innovation and science, Màire Geoghegan-Quinn, will take part in the opening session.
9-11 May 2012, Aachen
Featuring over 500 participants, around 70 conference speakers and over 30 sponsors, this event has established a reputation as Germany’s leading forum for applications of laser technology in the production environment. All lectures are available in both German and English. In addition we will present to you typical future applications of the latest laser systems and processes in the applications center of the Fraunhofer ILT.
10-11 May 2012, Baltimore
This meeting will bring together experts from the biological industry, academia and regulatory agencies to review the possibility of introducing new selected biomarkers in the assessment of vaccine safety at pre-clinical and early clinical stages (inflammation and early immunological events).